1. Preliminary hazard assessment of a new nature-inspired antifouling (NIAF) agent.
- Author
-
Vilas-Boas C, Sousa J, Lima E, Running L, Resende D, Ribeiro ARL, Sousa E, Santos MM, Aga DS, Tiritan ME, Ruivo R, Atilla-Gokcumen GE, and Correia-da-Silva M
- Subjects
- Animals, Water Pollutants, Chemical toxicity, Aliivibrio fischeri drug effects, Xanthones toxicity, Mytilus drug effects, Mytilus physiology, Diatoms drug effects, Humans, Daphnia drug effects, Daphnia physiology, Artemia drug effects, Biofouling prevention & control
- Abstract
A recently synthesized aminated 3,4-dioxygenated xanthone (Xantifoul2) was found to have promising antifouling (AF) effects against the settlement of the macrofouler Mytilus galloprovincialis larvae. Preliminary assessment indicated that Xantifoul2 has reduced ecotoxicological impacts: e.g., being non-toxic to the marine crustacea Artemia salina (<10 % mortality at 50 μM) and showing low bioconcentration factor in marine organisms. In order to meet the EU Biocidal Product Regulation, a preliminary hazard assessment of this new nature-inspired antifouling (NIAF) agent was conducted in this work. Xantifoul2 did not affect the swimming ability of the planktonic crustacean Daphnia magna, the growth of the diatom Phaeodactylum tricornutum, and the cellular respiration of luminescent Gram-negative bacteria Vibrio fischeri, supporting the low toxicity towards several non-target marine species. Regarding human cytotoxicity, Xantifoul2 did not affect the cell viability of retinal human cells (hTERT-RPE-1) and lipidomic studies revealed depletion of lipids involved in cell death, membrane modeling, lipid storage, and oxidative stress only at a high concentration (10 μM). Accelerated degradation studies in water were conducted under simulated sunlight to allow the understanding of putative transformation products (TPs) that could be generated in the aquatic ecosystems. Both Xantifoul2 and photolytic-treated Xantifoul2 in the aqueous matrix were therefore evaluated on several nuclear receptors (NRs). The results of this preliminary hazard assessment of Xantifoul2, combined with the high degradation rates in water, provide strong evidence of the safety of this AF agent under the evaluated conditions, and provide the support for future validation studies before this compound can be introduced in the market., Competing Interests: Declaration of competing interest Marta Correia-da-Silva has patent Xanthonic compounds and their use as antifouling agents issued to CN113226035. Emilia Sousa has patent Xanthonic compounds and their use as antifouling agents issued to CN113226035. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF